Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia

This trial is studying a drug called gemtuzumab ozogamicin (GO) to treat a very small amount of remaining leukemia — called measurable residual disease (MRD) — in patients with acute myeloid leukemia (AML) who are otherwise in remission. **You may be eligible if...** - You have been diagnosed with AML (a type of blood cancer) - You are technically in remission (less than 5% abnormal cells in bone marrow) but a very sensitive test still detects residual leukemia cells - Your leukemia has the CD33 protein marker on its surface - You are in generally good health with acceptable organ function - You are 18 years or older **You may NOT be eligible if...** - You have acute promyelocytic leukemia (APL) or mixed-cell leukemia - You have active, measurable leukemia (not just MRD) - You have had a prior severe reaction to GO - You have serious liver disease or other organ problems Talk to your doctor to see if this trial is right for you.